You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Ritonavir
Ritonavir is a HIV-1 and HIV-2 protease inhibitor (EC50 values are 0.022-0.13 and 0.16 μM, respectively). Blocks the metabolism of protease inhibitors by liver enzyme cytochrome P450-3A4 (CYP3A4). Orally bioavailable. When used in combination with lopinavir, improves outcome in an animal model of MERS-CoV infection.
Compound Libraries for Ritonavir
Technical Data for Ritonavir
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Ritonavir
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||14.42||20 with gentle warming|
Preparing Stock Solutions for Ritonavir
The following data is based on the product molecular weight 720.94. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||6.94 mL||34.68 mL||69.35 mL|
|1 mM||1.39 mL||6.94 mL||13.87 mL|
|2 mM||0.69 mL||3.47 mL||6.94 mL|
|10 mM||0.14 mL||0.69 mL||1.39 mL|
References for Ritonavir
References are publications that support the biological activity of the product.
Kempf et al (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc.Natl.Acad.Sci.U.S.A. 92 2484 PMID: 7708670
Kempf et al (1998) Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J.Med.Chem. 41 602 PMID: 9484509
Zeldin et al (2004) Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J.Antimicrob.Chemother. 53 4 PMID: 14657084
Chan et al (2015) Treatment with Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J.Infect.Dis. 12 1904 PMID: 26198719
If you know of a relevant reference for Ritonavir, please let us know.
View Related Products by Product Action
Keywords: Ritonavir, Ritonavir supplier, HIV-1, HIV-2, proteases, inhibitors, inhibits, cytochrome, P450-3A4, human, immunodeficiency, virus, orally, active, MERS-CoV, middle, east, respiratory, syndrome, coronaviruses, ABT-538, A-84538, Abbot, 84538, COVID-19, HIV, Protease, Coronavirus, 5856, Tocris Bioscience
1 Citation for Ritonavir
Citations are publications that use Tocris products. Selected citations for Ritonavir include:
Matthew B et al (2021) The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia. Sci Transl Med 13 PMID: 34408078
Do you know of a great paper that uses Ritonavir from Tocris? Please let us know.
Reviews for Ritonavir
There are currently no reviews for this product. Be the first to review Ritonavir and earn rewards!
Have you used Ritonavir?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image